Stock Analysis
The Cooper Companies, Inc. Common StockCOO
P/E 19.32×· 5Y range 6.38–70.78×· bottom 15% of history
Sector: Healthcare · Industry: Ophthalmic Goods
AnalystsBuy23 analystsP/E 19.3× sits at the 15th percentile of its 5.089664613278576-year history.
Cash covers 5% of debt · Q1 2026.
PMP Verdict
Mixed fundamentals, cheap valuation
Strengths
- Quality90
- Financial Health60
Risks
- Growth37
- Profitability42
Mixed business trading cheap — priced for skepticism.
Bull Case
- ✓P/E 19.3× at bottom 15% of 5-year history
What's happening with COO
Profile
Strong earnings quality and valuation; growth and profitability lag behind.
How is each axis scored?
- Valuation77/100 · Strong
- P/E vs own history (15th pct)25/25
- FCF yield (6.2%)20/25
- P/S (2.6x)20/25
- EV/EBIT (24.4x)12/25
- Growth37/100 · Weak
- Revenue CAGR (8.8%)12/25
- Net income CAGR (-40.3%)0/25
- EPS CAGR 5Y (-40.3%)0/25
- Fwd implied growth (62.1%)25/25
- Profitability42/100 · Weak
- ROIC (4.0%)5/25
- ROE (6.8%)5/25
- Net margin (13.5%)20/25
- Operating margin (12.8%)12/25
- Financial Health60/100 · Moderate
- Altman Z (2.74)18/25
- Current ratio (1.34)12/25
- Interest coverage (5.4x)18/25
- Net cash / debt (D/A 19%)12/25
- Quality90/100 · Strong
- Piotroski F (6/9)15/25
- Beneish M (-2.55)25/25
- FCF conversion (119%)25/25
- Margin stability (σ 2.7%)25/25
- Moat68/100 · Moderate
- ROIC >12% years (0/10 yrs)0/25
- Median gross margin (65.1%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 5.5%)18/25
About The Cooper Companies, Inc. Common Stock
CooperCompanies is one of the largest eyecare companies in the US. Show more
It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Headquarters: SAN RAMON, CA · Employees: 15,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
77B+P/E (TTM)19.2xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 6.4x–70.8x · 15th pct
P/FCF15.6xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield6.2%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 0.6%–6.7% · 98th pct
P/S (TTM)2.58xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 2.4x–7.8x · 2nd pct
EV/EBIT24.4xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 20.2x–49.5x · 16th pct
EV/Sales3.1xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E11.8xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio1.31xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio3.49D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield0.00%B
Grade B: NoneTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio1.6%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
42D+ROIC4.0%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE6.8%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA4.6%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin13.5%A
Grade A: HighNet Income / Revenue
Operating Margin12.8%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin65.9%A
Grade A: PremiumGross Profit / Revenue
FCF Margin16.0%A
Grade A: HighFCF / Revenue
True FCF Margin14.3%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
37DRevenue CAGR8.8%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-40.3%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-40.3%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth62.1%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-4.3%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income12.4%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.7%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
60BAltman Z-Score2.74C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.34xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.51xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage5.4xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment3.5yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT4.4xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity0.30xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.05xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
90A+Piotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.55A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion118.9%A
Grade A: StrongFCF / Net Income
Margin Stability2.7%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue8.4%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.34xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Kurzius Lawrence Erik Filed | Kurzius Lawrence Erik | BuyOpen market buy | +10.0K | |
Rosebrough Walter M Jr Filed | Rosebrough Walter M Jr | BuyOpen market buy | +3.0K | |
Kurzius Lawrence Erik Filed | Kurzius Lawrence Erik | BuyOpen market buy | +10.0K | |
Keel Paul A Filed | Keel Paul A | BuyOpen market buy | +4.7K | |
Rosebrough Walter M Jr Filed | Rosebrough Walter M Jr | BuyOpen market buy | +7.0K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Keel Paul A Filed | Keel Paul A | Grant / award | +2.8K | |
Rosebrough Walter M Jr Filed | Rosebrough Walter M Jr | Option exercise | -832 | |
Rosebrough Walter M Jr Filed | Rosebrough Walter M Jr | Option exercise | +832 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
68BROIC >12% Years0/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)65.1%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor5.5%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$3.00
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$0.81
Cash & short-term investments per share (Finnhub)
Book Value / Share$43.81
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$2.50B
Total debt obligations (short + long term)
Cash & Equiv.$124.90M
Cash and short-term investments
Net Debt$2.37B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$8.36B
Shareholders' equity (book value)
Asset / Liability3.06xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$10.93B
Current Market Capitalization
Beta0.83B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jul 2026 · Ratio snapshot Oct 17, 2026
Key Insights: The Cooper Companies, Inc. Common Stock (COO)
COO is up 0.94% at the last close. Piotroski F-Score of 6/9 indicates mixed fundamentals for The Cooper Companies, Inc. Common Stock. Altman Z-Score of 2.74 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -2.55 suggests a low likelihood of earnings manipulation.
- The Cooper Companies, Inc. Common Stock converts about 16% of revenue into free cash flow — strong cash generation.
- Takes ~3.5 years to repay net debt from free cash flow.
- At a valuation score of 77/100, COO trades near the cheapest end of its own historical range (P/E 19.2).
See how COO ranks on the Capex Tracker — top 50 capital spenders compared.
Earnings
View earnings calendar →Recent Earnings Results
| Date | Time | EPS Est. | EPS Actual | Surprise | Rev Est. | Rev Actual |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | After-Hrs | $1.13 | $1.15 | +1.8% | $1.1B | $1.1B |
Recent Market Moves
See all COO moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 57.30 | +4.41% | 2.70 |
| Oct 15 | After-hours | 57.21 | +4.25% | 2.60 |
Frequently Asked Questions about COO
What is the current The Cooper Companies, Inc. Common Stock (COO) stock price?
COO is trading at $57.94 at the last market close, up 0.94% on the session. PreMarketPrice tracks COO pre-market, intraday and after-hours prices.
Is COO stock a buy right now?
PreMarketPrice's quantitative model rates The Cooper Companies, Inc. Common Stock's financial health at 60/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is COO stock overvalued?
The Cooper Companies, Inc. Common Stock trades at a trailing P/E of 19.2 and our valuation score rates it 77/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does The Cooper Companies, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for COO. The Earnings section lists recent reports and updates as dates are announced.
What sector does The Cooper Companies, Inc. Common Stock operate in?
The Cooper Companies, Inc. Common Stock operates in the Healthcare sector, within the Ophthalmic Goods industry. The Related Stocks section lists sector peers for comparison.
What does The Cooper Companies, Inc. Common Stock do?
CooperCompanies is one of the largest eyecare companies in the US.
About The Cooper Companies, Inc. Common Stock (COO) Stock
The Cooper Companies, Inc. Common Stock (COO) is a US-listed stock operating in the Healthcare sector, specifically the Ophthalmic Goods industry. As of the latest update, The Cooper Companies, Inc. Common Stock is trading at $57.94, up 0.94% on the day with a market capitalization of $10.9 billion. The financial health score for COO is 60/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for COO stock.
COO Stock Analysis & Key Metrics
On PreMarketPrice, you can track The Cooper Companies, Inc. Common Stock (COO) across multiple dimensions:
- Pre-market price & movement: Real-time COO stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Earnings calendar: Upcoming and past earnings reports for COO, including EPS estimates, actual results, and surprise percentages.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for COO with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for The Cooper Companies, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 60/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for COO.
- Sector peers: Compare COO against 4 other healthcare stocks on key financial metrics.
Is COO a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate The Cooper Companies, Inc. Common Stock (COO) as an investment. The financial health score of 60/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average. Earnings data reveals whether the company is meeting or beating analyst expectations.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.The Cooper Companies, Inc. Common Stock (COO) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.